Effect of antifibrotic agents on postoperative complications after lung transplantation for idiopathic pulmonary fibrosis

Abstract

AbstractBackgroundAntifibrotic agents (AFAs) are now standard‐of‐care for idiopathic pulmonary fibrosis (IPF). Concerns have arisen about the safety of these drugs in patients undergoing lung transplantation (LTx).MethodsWe performed a multi‐centre, nationwide, retrospective, observational study of French IPF patients undergoing LTx between 2011 and 2018 to determine whether maintaining AFAs in the peri‐operative period leads to increased bronchial anastomoses issues, delay in skin healing and haemorrhagic complications. We compared the incidence of post‐operative complications and the survival of patients according to AFA exposure.ResultsAmong 205 patients who underwent LTx for IPF during the study period, 58 (28%) had received AFAs within 4 weeks before LTx (AFA group): pirfenidone in 37 (18.0%) and nintedanib in 21 (10.2%). The median duration of AFA treatment before LTx was 13.8 (5.6–24) months. The AFA and control groups did not significantly differ in airway, bleeding or skin healing complications (p = 0.91, p = 0.12 and p = 0.70, respectively). Primary graft dysfunction was less frequent in the AFA than control group (26% vs. 43%, p = 0.02), and the 90‐day mortality was lower (7% vs. 18%, p = 0.046).ConclusionsAFA therapy did not increase airway, bleeding or wound post‐operative complications after LTx and could be associated with reduced rates of primary graft dysfunction and 90‐day mortality.